Antares Pharma, Inc. (ATRS) Given Average Recommendation of “Buy” by Brokerages
Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have received an average rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $3.94.
A number of equities research analysts recently commented on ATRS shares. Raymond James Financial, Inc. started coverage on Antares Pharma in a report on Thursday, April 20th. They issued a “strong-buy” rating and a $4.30 price objective for the company. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Antares Pharma in a report on Friday, June 23rd. Chardan Capital began coverage on Antares Pharma in a report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target for the company. Finally, Vetr downgraded Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 price target for the company. in a report on Monday, June 26th.
In other Antares Pharma news, insider Fred M. Powell purchased 130,000 shares of the stock in a transaction on Friday, June 9th. The stock was bought at an average cost of $2.79 per share, for a total transaction of $362,700.00. Following the completion of the acquisition, the insider now directly owns 331,434 shares of the company’s stock, valued at $924,700.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.60% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the company. KCG Holdings Inc. boosted its position in Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 21,881 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Antares Pharma by 10.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 289,093 shares of the specialty pharmaceutical company’s stock valued at $822,000 after buying an additional 26,847 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Antares Pharma by 20.1% in the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock valued at $476,000 after buying an additional 28,029 shares in the last quarter. Thompson Davis & CO. Inc. boosted its position in Antares Pharma by 80.8% in the first quarter. Thompson Davis & CO. Inc. now owns 68,386 shares of the specialty pharmaceutical company’s stock valued at $194,000 after buying an additional 30,560 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Antares Pharma by 4.8% in the first quarter. Geode Capital Management LLC now owns 958,234 shares of the specialty pharmaceutical company’s stock valued at $2,721,000 after buying an additional 43,629 shares in the last quarter. Institutional investors own 32.04% of the company’s stock.
Antares Pharma (NASDAQ ATRS) traded down 1.92% during trading on Friday, hitting $3.07. The company had a trading volume of 321,034 shares. The firm has a 50-day moving average of $3.02 and a 200 day moving average of $2.68. Antares Pharma has a 12-month low of $0.98 and a 12-month high of $3.37. The company’s market capitalization is $478.69 million.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. The business had revenue of $12.01 million during the quarter, compared to the consensus estimate of $12.10 million. Antares Pharma had a negative return on equity of 45.05% and a negative net margin of 41.26%. On average, equities research analysts forecast that Antares Pharma will post ($0.13) earnings per share for the current year.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.